PDF(Pubmed)
Abstract：
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
摘要：
全球大多数癌症的死亡人数正在下降，但是在英国和其他西方国家，肝细胞癌（HCC）的发病率和死亡率正在增加。肝癌是一种高度致命的癌症，经常诊断晚，发病率与死亡率之比接近1。尽管有许多治疗选择，包括那些与良好的中长期生存有关的，在英国，肝癌的5年生存率仍低于20%。性,种族和贫困是发病率的重要人口统计学，和/或生存，HCC。这些临床实践指南将为HCC患者的评估和管理提供循证建议。详细总结了支持我们提出的建议的临床和科学数据。大部分内容将具有广泛的相关性，但治疗算法是基于在英国可用的疗法，并已获得国家卫生服务的监管批准。
